Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2127 of 6351
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingRATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignan…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental drug ataluren tested for safety in duchenne MD patients
Disease control CompletedThe objective of this study is to assess the safety and tolerability of 10, 10, 20 milligrams per kilogram (mg/kg) ataluren in participants with nmDBMD who had prior exposure to ataluren in a PTC sponsored clinical trial or treatment plan, and siblings of those participants (prov…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Stem cell retreatment shows promise for tough Crohn's cases
Disease control CompletedTo provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.
Phase 3 • Sponsor: Mesoblast, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Proton beam radiation aims to spare healthy tissue in breast cancer treatment
Disease control OngoingThis phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to norm…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a viagra drug heal scleroderma finger sores?
Disease control CompletedDigital ulcers (DUs) are an expression of the microangiopathy in patients with scleroderma (SSc). DUs lead to pain and impaired hand use. DUs remain a severe complication for many patients and effective therapy remains elusive. In the present study, the investigators propose to e…
Phase 3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a cancer drug ease sickle cell pain? early trial launches
Disease control Recruiting nowThe goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor. HDAC inhibitors have been shown to significantly increase …
Phase 1 • Sponsor: Abdullah Kutlar • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Weekly shot could replace daily hormone injections for adults
Disease control CompletedThis study investigates the safety, tolerability, pharmacokinetic profile (PK), and pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared to one dose-level of an approved daily human growth hormone product over a period of 4 weeks (4 weekly …
Phase 2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can Omega-3s and a prostate drug keep Low-Risk cancer in check?
Prevention OngoingThe purpose of this study is to determine whether marine omega-3 fatty acids and 5-alpha-reductase inhibitor are effective in the progression of prostate cancer for low-risk prostate cancer patients.
Sponsor: CHU de Quebec-Universite Laval • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
Fish oil treatment shows promise for liver disease in kids on IV feeding
Disease control CompletedUse of a fish oil emulsion to decrease liver disease due to long term intravenous nutrition.
Phase 3 • Sponsor: Kapiolani Medical Center For Women & Children • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare ovarian cancer: which chemo combo works best?
Disease control OngoingThis randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as first-line therapy in treating patients with newly dia…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can mapping rare genetic variants unlock better care for autism-related disorders?
Knowledge-focused Recruiting nowSimons Searchlight is an observational, online, international research program for families with rare genetic variants that cause neurodevelopmental disorders and may be associated with autism. Simons Searchlight collects medical, behavioral, learning, and developmental informati…
Sponsor: Simons Searchlight • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Which radiation schedule tames spreading cancer best? new study aims to find out
Symptom relief OngoingThe purpose of this study is to find out which way of giving high-dose radiation works best for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. This study will look at the effects, good and/or bad, of giving 27 Gy in three fractions (3 days) o…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Could a new drug combo boost transplant success in lymphoma?
Disease control CompletedThe standard of care therapy for DLBCL in the relapsed setting is RICE with the plan for the patient to proceed to transplant. This protocol will add Revlimid to the first 7 days of the RICE therapy and again after transplant as maintenance. To improve over all outcome and surviv…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Hunting for hidden genes behind albinism
Knowledge-focused CompletedThe oculocutaneous albinism is an autosomal recessive condition associated with mutations in 4 genes. In 20% of patients no mutation is identified. The optimization of genetic analysis methods and the search for new genes involved will help improve the diagnosis in these patients…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Giving patients the keys: Self-Controlled hospital stays may curb forced admissions
Disease control CompletedBrief Admission by self-referral (BA) is a standardized treatment model, providing patient-controlled and person-centered care. It was developed to reduce self-harm and compulsory care by promoting autonomy. Randomized clinical trials have not yielded significant between group di…
Sponsor: Region Skane • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for rare cancer: drug combo shows promise in advanced angiosarcoma
Disease control CompletedEfficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Virus therapy takes on Drug-Resistant colorectal cancer
Disease control CompletedThe purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux treatments.
Phase 1 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Low-Dose tamoxifen may shield radiation survivors from breast cancer
Prevention OngoingEstrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radia…
Phase 2 • Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jun 27, 2026 08:09 UTC
-
Supercharged immune cells take on viruses in transplant patients
Disease control CompletedThe main purpose of this project is to evaluate the efficiency of the injection of CD4 and CD8+ T cell anti-Cytomegalovirus (CMV) on blood viral replication of CMV, 21 days after the first injection (adenovirus infection is not enough usual, especially in adults, to be used for t…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 13:25 UTC